Project Grant R42HL099150

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $306,870 to Kinetiq Therapeutics LLC, a life science startup in Texas, to conduct proof-of-concept studies on an enzyme replacement therapy (ERT) for Fanconi anemia. Fanconi anemia is a rare inherited disease characterized by bone marrow failure and malignancies. The project aims to demonstrate the feasibility of using an...

Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Leland Stanford Junior University a Project Grant of $662,949 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop innovative cell and gene therapy strategies for treating Fanconi Anemia (FA). The research aims to establish functional hematopoietic stem and progenitor cells (HSPCs) in the bone marrow that can maintain hematopoiesis without...

The Department of the Army Medical Command awarded a $519,702 Project Grant to Stanford University under the Military Medical Research and Development program (CFDA 12.420). The two-year grant will support Stanford's development of non-genotoxic hematopoietic stem cell transplantation regimens for Fanconi anemia. Fanconi anemia is a rare genetic disorder that can cause bone marrow failure and blood cancers. The Military Medical Research and Development program aims to advance medical solutions...

Grant Award Summary Gigamune, Inc. received an $800,000 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) awarded on September 15, 2025, with a completion date of August 31, 2026. Under the direction of Principal Investigator David Scott Johnson, Ph.D., the company is developing a novel lentiviral vector technology to enable enhanced in vivo delivery of T cell receptors (TCRs) for cell therapy targeting Stage IV metastatic...

This three-year, $1 million Project Grant from the National Science Foundation's Biological Sciences program (CFDA 47.074) supports the development of viral vectors for gene delivery and manipulation in amphibian research. The Trustees of Columbia University will lead efforts to design new viral vectors with host specificity for amphibians. Researchers at Columbia, the Institute of Science and Technology Austria, the University of Utah, and the Scripps Research Institute will collaborate to test...

Summary The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded The Leland Stanford Junior University a Project Grant of $460,349 under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) on May 8, 2026, with completion targeted for February 28, 2030. The award funds development of a novel cell-based therapeutic delivery platform termed TRANSFER (Trogocytosis-Based Transfer and Functional Effector Release),...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) provides $364,167 to Villanova University to develop novel non-viral gene delivery methods for cell therapies. The key objectives are: The Bracaglia Lab will develop new polymeric gene delivery vehicles to improve the delivery of siRNAs and other payloads to T cells and hematopoietic stem cells (HSCs). Drs. Elmer and Huang will...

Federal Project Grant Award Summary Emprime Therapeutics Inc. received a $314,363 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded on September 15, 2025, with completion targeted for August 31, 2026. The award funds development of a novel dual adeno-associated virus (AAV) vector technology called STITCHR (Specific Trans-Ligation of Cognate RNA) designed to deliver and express full-length Factor VIII...

This Small Business Innovation Research (SBIR) Phase I project, funded by the National Science Foundation's Directorate for Technology, Innovation, and Partnerships (CFDA 47.084) with $305,000 obligated, develops a novel gene therapy platform designed to overcome the cargo size limitations of adeno-associated virus (AAV) vectors. The project addresses a critical unmet need in genomic medicine by enabling the delivery of oversized genes that are currently incompatible with AAV-based gene...

Grant Award Summary Emory University received a Project Grant award of $860,750 from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), effective June 1, 2025, through May 31, 2027. The award funds research to improve the reach and efficacy of adeno-associated virus (AAV)-based gene therapy by utilizing endogenously produced extracellular vesicles (EVs) to transport engineered transgene...